VIA
KROS icon

Virtus Investment Advisers’s Keros Therapeutics KROS Stock Holding History

Virtus Investment Advisers’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$140K Buy
12,676
+309
+2% +$4.77K 0.04% 444
2025
Q4 		$252K Buy
12,367
+4,025
+48% +$70.6K 0.07% 326
2025
Q3 		$132K Buy
8,342
+1,448
+21% +$21.4K 0.04% 396
2025
Q2 		$92K Sell
6,894
-2,013
-23% -$27.2K 0.03% 367
2025
Q1 		$90.8K Buy
+8,907
New +$103K 0.02% 433
2023
Q3 		– Sell
-2,953
Closed -$119K – 272
2023
Q2 		$119K Sell
2,953
-5,422
-65% -$238K 0.08% 235
2023
Q1 		$358K Buy
8,375
+262
+3% +$13.2K 0.25% 120
2022
Q4 		$390K Hold
8,113
– – 0.26% 121
2022
Q3 		$305K Buy
+8,113
New +$281K 0.14% 143

Other funds holding KROS

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $70.4B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return